A fractional CMO onboarding checklist gives a MedTech CEO a practical framework for turning a new marketing engagement into an organized working relationship. Before the CMO begins, align on business priorities, decision authority, team responsibilities, data access, reporting expectations, and the compliance review process.
Use this checklist to guide the first 90 days, from initial immersion and a marketing audit through strategy development and execution. The goal is not to prescribe identical targets for every company. It is to help the CEO and fractional CMO establish clear priorities, choose relevant metrics, involve the right stakeholders, and create a repeatable cadence for reviewing progress and adjusting the plan.
What a Fractional CMO Should Own
A fractional CMO is a senior marketing leader engaged on a part-time or contract basis. The person may guide positioning, demand generation, product marketing, customer acquisition, team development, agency management, measurement, or other priorities. The exact schedule, scope, and engagement length depend on the company’s needs.
The role should not be confused with a general marketing advisor or an extra pair of hands. A fractional CMO normally needs enough authority to set direction, make agreed decisions, assign work, and hold contributors accountable. At the same time, the CEO retains responsibility for defining business priorities and ensuring that the CMO has access to the people, information, and resources required to lead.
In a MedTech company, marketing leadership also operates within established legal, regulatory, privacy, clinical, and quality controls. A fractional CMO can coordinate marketing work with the appropriate specialists, but should not be treated as the sole source of compliance approval or legal advice.
The Five-Part Fractional CMO Onboarding Checklist
The following five parts cover preparation, immersion, diagnosis, strategy, and execution. CEOs can adapt the timing to the company’s sales cycle, operating stage, internal capacity, and regulatory obligations. This fractional CMO onboarding playbook provides a companion framework for CEOs managing the process.
1. Complete Pre-Boarding Alignment
Before the engagement begins, document why the company is bringing in a fractional CMO. A broad instruction to “grow marketing” is not enough. Identify the business problem, the desired decisions, and the areas the CMO is expected to influence.
- Define the mandate: State whether the immediate need is strategic planning, market positioning, pipeline development, a launch, team leadership, agency oversight, measurement, or a combination of priorities.
- Set the scope: List the brands, products, markets, customer groups, channels, and teams included in the engagement.
- Clarify decision rights: Specify what the CMO can approve, what requires CEO or executive approval, and what must follow legal, regulatory, privacy, clinical, or quality review.
- Confirm resources: Discuss the available budget, internal capacity, outside partners, technology, and practical constraints.
- Agree on deliverables: Define the expected outputs for the initial assessment, strategy, reporting, team development, and execution period.
- Set communication expectations: Establish meeting frequency, reporting format, response expectations, and the primary contacts for urgent decisions.
Create a short engagement brief that records these agreements. It should be specific enough to guide the work while leaving room for the CMO to revise recommendations after reviewing the evidence.
2. Organize First-Week Immersion
The first week should help the fractional CMO understand how the business actually operates. Presentations are useful, but conversations with the people closest to customers, products, revenue, and delivery often reveal where written plans differ from daily practice.
- Introduce the CMO to leaders in sales, product, finance, customer success, operations, legal, regulatory, privacy, clinical, and quality functions as applicable.
- Explain the business model, priority products, customer segments, buying process, sales cycle, revenue structure, and strategic constraints.
- Share the current positioning, approved claims, brand standards, campaign plans, sales materials, customer research, and product roadmap.
- Provide appropriate access to analytics, customer relationship management data, campaign platforms, project systems, budgets, contracts, and previous reports.
- Explain how content, product claims, data collection, and campaign materials are reviewed and approved.
- Identify unresolved disagreements, delayed initiatives, resource gaps, and decisions awaiting executive direction.
Access should follow the company’s security and privacy policies. Give the CMO what is necessary for the agreed role, but do not bypass established controls or share sensitive information without an appropriate business purpose.
3. Conduct a Days 1-30 Marketing Audit
During the first 30 days, the fractional CMO should build a fact-based view of the current marketing system. The audit should identify what is working, what is unclear, and what is preventing the team from executing effectively. It should not become an indefinite research project.
The audit may cover positioning, customer segments, buyer needs, competitive context, channel performance, website paths, lead management, sales handoffs, content, product marketing, customer retention activity, agency relationships, technology, reporting, team roles, and approval workflows. The depth of each area should reflect the engagement mandate.
Ask the CMO to separate findings into four categories: reliable strengths, material risks, unanswered questions, and prioritized opportunities. Each recommendation should identify the evidence behind it, the likely business relevance, the responsible owner, and any dependencies. In MedTech, dependencies may include claim substantiation, product status, privacy requirements, clinical review, or approval for a particular market.
The initial audit should end with an executive discussion, not simply a slide presentation. The CEO and CMO should agree on which findings require immediate action, which require more evidence, and which will remain outside the current scope.
4. Build a Days 31-60 Strategy and Operating Plan
Once the baseline is understood, translate the findings into a focused plan. A useful marketing strategy makes choices. It identifies the priority audience, the problem the company is prepared to address, the positioning to emphasize, the channels to use, and the work the team will deliberately postpone.
- Business objective: Connect marketing priorities to a defined company goal rather than treating activity volume as the outcome.
- Audience and buying group: Document who influences the decision, what each stakeholder needs, and where sales or marketing lacks useful insight.
- Positioning and messaging: Clarify the value proposition and create a process for reviewing product or clinical claims before use.
- Priority initiatives: Rank campaigns, content, product marketing, sales enablement, customer programs, and operational improvements by relevance and feasibility.
- Ownership: Assign one accountable owner to each initiative and identify contributors, approvers, deadlines, and dependencies.
- Measurement: Establish a small set of decision-useful indicators, their definitions, data sources, and reporting cadence.
- Risk controls: Record the legal, regulatory, privacy, quality, operational, and reputational reviews required before launch.
Review the plan with the people expected to implement or approve it. This is a practical way to uncover unrealistic timelines, missing expertise, data limitations, and review bottlenecks before they disrupt execution.
5. Begin Days 61-90 Execution and Review
The final part of the initial plan moves selected priorities into execution. The goal is not to launch every possible initiative by day 90. It is to establish a dependable operating rhythm and demonstrate that the company can move approved work from decision to delivery.
- Launch the highest-priority approved initiatives with named owners and documented deadlines.
- Track delivery, response, pipeline movement, and other relevant indicators using agreed definitions.
- Record assumptions and lessons so that the team can distinguish evidence from opinion.
- Resolve handoff problems between marketing, sales, product, and customer-facing teams.
- Review budget changes under the approval rules established with the CEO and finance team.
- Confirm that required reviews were completed and that final approved materials are retained according to company policy.
- Prepare a day-90 review covering progress, constraints, decisions needed, and priorities for the next period.
Results should be interpreted in context. A long buying cycle, limited baseline data, product readiness, or required reviews may affect what can reasonably be learned during the first 90 days. The CEO should evaluate the quality of decisions and operating improvements as well as near-term performance indicators.
Choose Metrics That Support Decisions
Metrics should help leaders decide what to continue, change, investigate, or stop. Avoid filling a dashboard with measures that have no clear owner or management use. The appropriate set depends on the company’s model, data quality, sales process, and stage of growth.
Leading Indicators
Leading indicators show whether work is progressing before final business outcomes are available. Examples may include qualified audience engagement, completed sales conversations, approved campaign assets, response by segment, lead acceptance, sales follow-up, opportunity creation, or movement through an agreed buying process.
A leading indicator is useful only when the team understands what it represents. For example, an increase in form submissions may mean little if submissions are poorly matched to the intended customer. Define qualification rules and review underlying quality rather than assuming that more activity is automatically better.
Lagging Indicators
Lagging indicators reflect outcomes that appear after marketing and sales activity has had time to work. Depending on the business, these may include accepted opportunities, closed revenue, acquisition cost, retention, expansion, or contribution margin. Attribution should be discussed carefully because multiple interactions and teams may influence the result.
Metric Definitions and Reporting
Create a simple metric dictionary that records the definition, source, owner, calculation method, and reporting frequency for each core measure. This prevents executives from using the same label for different numbers. Note known data limitations instead of presenting uncertain figures as precise.
Combine the dashboard with a concise written explanation: what changed, why it may have changed, what the team learned, and what decision is required. Weekly operating reviews can focus on active work and obstacles, while monthly or quarterly reviews can address trends, budget allocation, and strategic changes.
Integrate the Fractional CMO With the Team
A fractional executive cannot lead effectively from the edge of the organization. The CEO should present the CMO’s mandate to the team, explain why the role was created, and make clear how existing leaders will work with the new executive. This reduces uncertainty and prevents the CMO from being treated as either an outside auditor or an unaccountable advisor.
Culture
Explain how decisions are made, how disagreement is handled, and what behaviors the organization values. Invite candid input from employees who understand the company’s customers and operating constraints. The CMO should respect existing knowledge while remaining willing to challenge unsupported assumptions.
Communication
Define where decisions, project updates, approvals, and performance reports will live. A consistent system is more important than selecting a particular software platform. The CEO and CMO should also establish a direct channel for sensitive issues that should not wait for a routine meeting.
Authority
Document the CMO’s authority in practical terms. Can the CMO change campaign priorities, select vendors, reassign work, approve messaging, or adjust spending? Which decisions require the CEO, finance, product, legal, regulatory, privacy, clinical, or quality teams? Clear boundaries help the CMO act without creating unnecessary risk or repeated approval disputes.
Build MedTech Review Requirements Into the Workflow
MedTech marketing may be affected by requirements related to product status, claims, evidence, privacy, data use, promotional practices, and recordkeeping. The applicable obligations vary by product, audience, channel, and jurisdiction, and they can change. The company should obtain guidance from qualified legal, regulatory, privacy, clinical, and quality professionals where appropriate.
The fractional CMO’s job is to incorporate the company’s requirements into marketing operations. That may include identifying required reviewers, using approved claim language, documenting sources, routing materials through the correct approval process, tracking versions, and retaining final records according to company policy.
- Create an approval map showing which specialists review each type of marketing asset.
- Maintain a controlled source for approved positioning, product descriptions, and claims.
- Identify privacy and consent reviews before collecting, sharing, or using personal data.
- Account for jurisdiction-specific requirements when planning multi-market activity.
- Include review time in campaign schedules rather than treating approval as a final administrative step.
- Define how outdated or superseded materials will be withdrawn from use.
A fractional CMO can improve coordination and documentation, but cannot guarantee compliance or a particular regulatory outcome. Final determinations should remain with the qualified professionals and authorized company leaders responsible for those decisions.
Evaluate the Engagement at Day 90
The day-90 review should compare the engagement with the original mandate. Examine whether priorities are clearer, decisions are moving through the organization, ownership is defined, reporting is trustworthy, and approved initiatives are being executed. Review outcomes where enough time and data exist, but do not force conclusions from an incomplete sales cycle.
Decide whether to continue the same scope, narrow it, expand it, or prepare for a different leadership structure. Record the next period’s objectives, decision rights, resources, and review date. A fractional CMO arrangement may be temporary, may bridge a leadership transition, or may continue as an ongoing part-time role. The structure should follow the company’s needs rather than an assumed timetable.
Frequently Asked Questions
What should a CEO prepare before a fractional CMO starts?
Prepare an engagement brief, stakeholder list, current strategy, budgets, performance reports, customer and sales insights, team responsibilities, technology access, and relevant approval procedures. Identify known data gaps and unresolved decisions so the CMO can address them directly.
Who should participate in fractional CMO onboarding?
Participation depends on the company, but it commonly includes the CEO and leaders from marketing, sales, product, finance, operations, and customer-facing teams. MedTech onboarding may also require legal, regulatory, privacy, clinical, and quality stakeholders.
What should a fractional CMO deliver in the first 30 days?
The initial deliverable is usually a concise assessment of strengths, risks, unanswered questions, and prioritized opportunities. The exact output should match the agreed scope and distinguish supported findings from assumptions that need further investigation.
How should a CEO measure a fractional CMO?
Use measures connected to the engagement mandate and the company’s business model. Consider execution quality, team ownership, decision speed, reporting reliability, relevant leading indicators, and business outcomes that have had enough time to develop. Agree on definitions and data sources before evaluating results.
Can a fractional CMO approve MedTech compliance?
Not by default. A fractional CMO can coordinate workflows and follow established requirements, but legal, regulatory, privacy, clinical, and quality determinations should be made by the qualified specialists and authorized leaders responsible for them. Companies should seek appropriate professional review for their specific products, markets, and activities.
What happens after the 90-day onboarding plan?
The CEO and CMO should review evidence, constraints, team feedback, and changing business priorities. They can then confirm the next objectives, update the operating plan, adjust the engagement scope, and set another formal review date.